Search
Mesalazine
go.drugbank.com/drugs/DB00244ApprovedInvestigationalAlthough demonstrably effective in treating and maintaining remission for ulcerative colitis, mesalazine has historically faced a number of issues regarding its lack of stability as a pharmaceutical agent … An anti-inflammatory agent, structurally related to the salicylates and non-steroidal anti-inflammatory drugs like acetylsalicylic acid, which is active in inflammatory bowel disease [A174022].
Voacamine
go.drugbank.com/drugs/DB04877ExperimentalVoacamine is an alkaloid isolated from the bark of the _Pescheria fuchsiae folia_ tree. It is an antimalarial drug approved for use in several African countries.
GTI 2040
go.drugbank.com/drugs/DB05801InvestigationalGTI-2040 is a substance that is being studied as a treatment for cancer. It belongs to the family of drugs called antisense oligonucleotides.
Cilomilast
go.drugbank.com/drugs/DB03849InvestigationalIt is orally active and acts as a selective Phosphodiesterase-4 inhibitor. … Cilomilast (Ariflo, SB-207,499) is a drug which was developed for the treatment of respiratory disorders such as asthma and Chronic Obstructive Pulmonary Disease (COPD).
R1295
go.drugbank.com/drugs/DB05122ExperimentalR1295 is an integrin antagonist currently in clinical trials for the treatment of rheumatoid arthritis. … Integrins are associated to the pathology seen in some of the autoimmune diseases such as rheumatoid arthritis.
Apadenoson
go.drugbank.com/drugs/DB05009InvestigationalApadenoson is a selective A2a adenosine receptor agonist designed for use as a pharmacologic stress agent in cardiac perfusion imaging studies. … It is developed by Bristol-Myers Squibb and is in phase II of clinical trials.
Categories: Adenosine A receptor agonists, Adenosine A2 Receptor AgonistsPMI-001
go.drugbank.com/drugs/DB05730ExperimentalIt is an extract of the roots of an undisclosed perennial shrub which interferes with the production of IL-2 and COX-2 proteins, for the potential treatment of autoimmune diseases, such as rheumatoid arthritis … PMI-001 is a stand-alone, disease-modifying, anti-rheumatic drug (DMARD) being developed by Phytomedics Inc.
LU-31130
go.drugbank.com/drugs/DB05828ExperimentalIt acts at the Dopamine D4 receptors in the cortex and has low affinity for D2 receptors, adrenoceptors, muscarinic and histaminergic receptors. … LU-31130 is a rapid acting therapy developed by H. Lundbeck A/S to treat Psychosis, Schizophrenia and Schizoaffective Disorders.
Relugolix
go.drugbank.com/drugs/DB11853ApprovedInvestigationalRelugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. … administration - and therefore provides a less burdensome therapeutic option for patients who might otherwise require clinic visits for administration by healthcare professionals.